Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter

Oct 26 2023

• By Joseph Haas

Merck — Merck reported another strong quarter for Keytruda thanks to earlier-stage treatment

Related Content

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping

Mar 08 2023

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

Mar 07 2023

ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care

Oct 23 2023

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

Oct 23 2023

ESMO 23: Kelun/Merck, Hansoh ADCs Impress With Early Data In Breast Cancer

Oct 20 2023

Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs

Oct 20 2023

Five Key Takeaways From Merck’s Q2 Earnings Release

Aug 01 2023

Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy

Apr 17 2023

Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval

Apr 04 2023

Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients

Oct 10 2022

Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs

Dec 22 2022

Related Companies

Merck & Co., Inc.

Daiichi Sankyo Co., Ltd.

Seagen Inc.

Sichuan Kelun Pharmaceutical Co Ltd.

Acceleron Pharma, Inc.

Prometheus Biosciences Inc.

Additional Topics

Sales & Earnings Business Strategies ImmunoOncology Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window